The orexigenic and anabolic effects induced by ghrelin and the synthetic GH secretagogues (GHSs) are thought to positively contribute to therapeutic approaches and the adjunct treatment of a number of diseases associated with muscle wasting such as cachexia and sarcopenia. However, many questions about the potential utility and safety of GHSs in both therapy and skeletal muscle function remain unanswered. By using fura-2 cytofluorimetric technique, we determined the acute effects of ghrelin, as well as of peptidyl and nonpeptidyl synthetic GHSs on calcium homeostasis, a critical biomarker of muscle function, in isolated tendon-to-tendon male rat skeletal muscle fibers. The synthetic nonpeptidyl GHSs, but not peptidyl ghrelin and hexarelin, were able to significantly increase resting cytosolic calcium [Ca 2ϩ ] i . The nonpeptidyl GHS-induced [Ca 2ϩ ] i increase was independent of GHS-receptor 1a but was antagonized by both thapsigargin/caffeine and cyclosporine A, indicating the involvement of the sarcoplasmic reticulum and mitochondria. Evaluation of the effects of a pseudopeptidyl GHS and a nonpeptidyl antagonist of the GHS-receptor 1a together with a drug-modeling study suggest the conclusion that the lipophilic nonpeptidyl structure of the tested compounds is the key chemical feature crucial for the GHS-induced calcium alterations in the skeletal muscle. Thus, synthetic GHSs can have different effects on skeletal muscle fibers depending on their molecular structures. The calcium homeostasis dysregulation specifically induced by the nonpeptidyl GHSs used in this study could potentially counteract the beneficial effects associated with these drugs in the treatment of muscle wasting of cachexia-or other age-related disorders. (Endocrinology 154: 3764 -3775, 2013)
The orexigenic and anabolic effects induced by ghrelin and the synthetic GH secretagogues (GHSs) are thought to positively contribute to therapeutic approaches and the adjunct treatment of a number of diseases associated with muscle wasting such as cachexia and sarcopenia. However, many questions about the potential utility and safety of GHSs in both therapy and skeletal muscle function remain unanswered. By using fura-2 cytofluorimetric technique, we determined the acute effects of ghrelin, as well as of peptidyl and nonpeptidyl synthetic GHSs on calcium homeostasis, a critical biomarker of muscle function, in isolated tendon-to-tendon male rat skeletal muscle fibers. The synthetic nonpeptidyl GHSs, but not peptidyl ghrelin and hexarelin, were able to significantly increase resting cytosolic calcium [Ca 2ϩ ] i . The nonpeptidyl GHS-induced [Ca 2ϩ ] i increase was independent of GHS-receptor 1a but was antagonized by both thapsigargin/caffeine and cyclosporine A, indicating the involvement of the sarcoplasmic reticulum and mitochondria. Evaluation of the effects of a pseudopeptidyl GHS and a nonpeptidyl antagonist of the GHS-receptor 1a together with a drug-modeling study suggest the conclusion that the lipophilic nonpeptidyl structure of the tested compounds is the key chemical feature crucial for the GHS-induced calcium alterations in the skeletal muscle. Thus, synthetic GHSs can have different effects on skeletal muscle fibers depending on their molecular structures. The calcium homeostasis dysregulation specifically induced by the nonpeptidyl GHSs used in this study could potentially counteract the beneficial effects associated with these drugs in the treatment of muscle wasting of cachexia-or other age-related disorders. (Endocrinology 154: 3764 -3775, 2013) G hrelin, a 28-amino acid peptide produced by the oxyntic cells of the stomach, is the endogenous ligand for the GH secretagogue receptor (GHS-R) type 1a (1) . It has been proposed that ghrelin and GH secretagogues (GHSs) could be useful in some pathophysiological situations in which the hypothalamus-pituitary axis activity is impaired (2, 3) . A growing number of studies highlight the possible therapeutic effects of these molecules in diseases associated with muscle wasting, including anorexia nervosa, chronic obstructive pulmonary disease, functional dyspepsia, and chronic heart failure (4 -6), despite the necessity to assess the long-term efficacy and safety of GHSs therapies. Furthermore, the use of GHSs has been proposed to either prevent or treat the effects of aging and disuse on skeletal muscles (7) (8) (9) (10) . The synthesis of small peptides, pseudopeptides, and nonpeptidyl agonists to GHS-R1a has prompted novel approaches for their clinical use because such substances exhibit an equivalent efficacy to ghrelin and have a longer half-life and oral bioavailability (11) (12) (13) (14) . However, although the doseresponse relationships of GHSs have been characterized with regard to their effects on GH and IGF-1 secretion, their extraendocrine effects have not been fully characterized. For example, it has been proposed that GHSs can increase lean body mass in aged subjects (9, 15) , but studies focusing on their effects on muscle strength and physical performance revealed inconsistent results (8, 16) . It should be noted that ghrelin and its mimetics can also act through mechanisms not mediated by GH; thus the effects of GHSs on multiple target tissues such as heart, skeletal muscle, fat, and bone could be correlated to the molecular structure of the GHS used. Chronic ghrelin administration in cachectic patients with chronic heart failure resulted in increased food intake and improved left ventricular dysfunction, suggesting that ghrelin effectively antagonizes muscle atrophy in humans (17, 18) . However, it is widely known that the effects of ghrelin on the cardiovascular system are mediated by both GH-dependent and GH-independent mechanisms (19, 20) . Ghrelin and hexarelin have been shown to directly affect sarcomere shortening, transient intracellular Ca 2ϩ levels, L-type Ca 2ϩ channel opening, and outward K ϩ currents in isolated rat cardiomyocytes (21) (22) (23) . Furthermore, ghrelin directly inhibits apoptosis of cardiomyocytes and endothelial cells through pathways involving kinase-172 and Akt serine kinase (24) , whereas hexarelin protects rat cardiomyocytes from angiotensin II-induced apoptosis in vitro by modulating caspase activity and Bax/Bcl2 expression (25) . Although the therapeutic potential of GHSs in the treatment of cachexia and muscular wasting is high (4, 5, 26) , very little is known about the direct effects of peptidyl and nonpeptidyl GHSs on skeletal muscles. In previous studies, we documented that synthetic GHSs are capable of interfering with key processes involved in the excitability and excitation-contraction coupling of rat skeletal muscle (27) . GHSs caused a decrease of resting chloride conductance, an electrical parameter modulated by the calcium-dependent protein kinase C. Because resting chloride conductance controls the electrical stability of sarcolemma (28, 29) , this GHS-mediated effect could potentially produce an increase of muscle excitability and changes in the resistance to fatigue. Furthermore, in vitro application of GHSs caused a shift toward negative potentials of the mechanical threshold for contraction, which is a functional index of excitation-contraction coupling (27) . These findings led us to hypothesize that GHSs could directly interfere with calcium machinery, a critical determinant of muscle function. In this context, tendon-to-tendon isolated skeletal muscle fibers were used to study drug effects in a cellular system with intact Ca 2ϩ signaling machinery. This study was performed to analyze the acute effects of ghrelin and synthetic GHSs on calcium homeostasis in isolated native skeletal muscle fibers and to elucidate the intracellular signaling pathway involved in these effects. Among the non-peptidyl-based structures, we studied the effects of the spiropiperidine derivative L163 255 (a structural analogue of the lead compound MK-0677) and the triazole derivative JMV2801, both of which have been extensively investigated in animal studies (12, 30 -32) , as well as the effects of JMV1843, a pseudopeptoid agonist of GHS-R1a. Ghrelin and hexarelin were chosen as the peptidyl GHSs. The use of the cell viability tetrazolium assay and molecular modeling allowed us to gain insight into the mechanism of action of GHSs on skeletal muscle as well as to define the molecular requisite for producing alterations in calcium homeostasis.
Materials and Methods

Animal care and surgery
Animal care and all experimental protocols involving animals were in accordance with the European Directive 2010/63/EU and were approved by the Italian Ministry of Health. Adult male Wistar rats (Charles River Laboratories, Calco, Italy) weighing 300 -350 g were used. They had free access to food and tap water, were maintained at room temperature (22-24°C), and were exposed to a 12-hour light/12-hour dark cycle per day.
Dissection of native muscle fibers
The extensor digitorum longus (EDL) muscle was removed from each animal under deep urethane anesthesia (1.2 g/kg body weight). Immediately after the surgery, the rats were maintained under anesthesia and euthanized with an anesthetic overdose. EDL muscles were pinned in a dissecting dish containing 95% O 2 /5% CO 2 -gassed normal physiological solution (the composition of which is defined later) at room temperature (22°C) for further dissection. Small bundles of 10 -15 fibers arranged in a single layer were dissected lengthwise (tendon to tendon) with the use of microscissors, as previously described (33) .
Fura-2 fluorescence measurements in intact muscle fibers
Calcium measurements were performed using the membranepermeable Ca 2ϩ indicator fura-2 acetoxymethyl ester (fura-2 AM, Molecular Probes-Invitrogen, Monza, Italy). Loading of muscle fibers was performed for 2 hours at 25°C in normal physiological solution containing 5 M fura2-AM mixed to 0.05 % (vol/vol) Pluronic F-127 (Molecular Probes). After loading, muscle fibers were washed with normal physiological solution and mounted in a modified RC-27NE experimental chamber (Warner Instrument, Inc, Hamden, Connecticut) on the stage of an inverted Eclipse TE300 microscope (Nikon, Tokyo, Japan) with a 40ϫ Plan-Fluor objective (Nikon). The mean sarcomere length was set to 2.5-2.7 m. Fluorescence measurements were made using a QuantiCell 900 integrated imaging system (Visitech International Ltd., Sunderland, UK) as previously described (33, 34) .
During the experiments, pairs of background subtracted images of fura-2 fluorescence (510 nm) emitted after excitation at 340 and 380 nm were acquired and ratiometric images (340/380 nm) were calculated for each muscle fiber of the preparation using QC2000 software. Subsequently fluorescence ratio values were converted to the resting cytosolic calcium concentration, [Ca 2ϩ ] i (nM), after a calibration procedure using the following equation: [Ca 2ϩ ] i ϭ (R Ϫ R min )/(R max Ϫ R)*K D *␤ where R is the ratio of the fluorescence emitted after excitation at 340 nm to the fluorescence after excitation at 380 nm; K D is the affinity constant of fura-2 for calcium, which was taken as 145 nM (Molecular Probes); and ␤ is a parameter according to Grynkiewicz et al. (35) that was determined experimentally in situ in ionomycin-permeabilized muscle fibers as previously described (33) . R min and R max were determined in muscle fibers incubated in Ca 2ϩ -free normal physiological solution containing 10 mM EGTA and in normal physiological solution, respectively. To check for fiber integrity, preparations were stimulated by the addition of 100 mM K ϩ solution. Fibers that did not give rise to calcium transients after K ϩ treatment were discarded.
Determination of sarcolemmal permeability to divalent cations
The manganese quench technique was used to estimate the sarcolemmal permeability to divalent cations. Mn 2ϩ enters via the same routes as Ca 2ϩ but accumulates inside the cell. As Mn 2ϩ quenches the fluorescence of fura-2, the reduction of the fluorescence intensity can be used as an indicator of the time integral of Mn 2ϩ influx (36) . Muscle preparations were perfused for 2 minutes with normal physiological solution containing 0.5 mM MnCl 2 as a surrogate of CaCl 2 (quenching solution). During the quenching protocol, the fluorescence emission of fura-2 excited at 360 nm was acquired at 1 Hz.
Solution for fura-2 fluorescence measurements
The normal physiological solution was composed of 148 mM NaCl, 4.5 mM KCl, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 0.44 mM NaH 2 PO 4 , 12 mM NaHCO 3 , and 5.5 mM glucose. The pH of all solutions was adjusted to 7.3-7.4 by bubbling them with 95% O 2 /5% CO 2 . The calcium free-solution has the same composition as that of the normal physiological solution except that CaCl 2 was omitted and 10 mM EGTA was added. The quenching solution had the same composition except that 0.5 mM MnCl 2 was substituted for CaCl 2 .
Cell cultures and viability assay
C2C12 myocytes were cultured in DMEM supplemented with 10% fetal bovine serum, penicillin, streptomycin, and glutamine and were maintained at 37°C in 5% CO 2 /95% air. Reportedly, C2C12 cells express the GHS-R1a (37, 38) . Cell viability was assessed using the colorimetric [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt assay (cell counting kit, CCK8, VinciBiochem, Vinci, Italy) (39, 40) . Cells were seeded in 96-well cultures at a density of approximately 1 ϫ 10 4 cells per well and cultured for 18 hours to allow for attachment. The following day, the cells were treated with one of the test compounds (ghrelin, hexarelin, L163 255) dissolved in DMEM for 6 hours. Following exposure, 10 L of [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt pure solution was added into each well, and then the plate was incubated for an additional 2 hours. The absorbance at 450 nm was measured using a spectrophotometer (microplate reader Victor V31420 -40; PerkinElmer, Wellesley, Massachusetts). Cell viability (%) was expressed according to the following formula: cell viability (%) ϭ [(test value-blank)/ (control value-blank) ϫ 100], where the blank value represents that of a cell-free well and the control value represents that of wells of cells treated with the vehicle alone (0.1% dimethysulfoxide).
Molecular modeling study
The lowest energy conformers for each drug were searched using a systematic Merck Molecular Force Field analysis in the presence of water. A restricted number of conformers were found in the range of 3 kcal/mol on the basis of the Boltzmann distribution. The molecules were first constructed by fragments, and the molecular geometry was optimized to DFT B3LYP/6 -31G* level theory and then submitted for a systematic Merck Molecular Force Field conformational analysis.
It was observed that the most populated low-energy conformer families were within the 3 kcal/mol range; among them, the lowest energy conformer was selected and used for the overlay. The conformers were superimposed at the level of the aminoacylamido groups and the near stereocenters with configuration R for the nonpeptidyl structures and JMV1843. The conformers were also superimposed at the same stereocenter and the amide bond for JMV1843 and hexarelin.
All calculations were performed with the SPARTAN '06 package (Wavefunction, Inc, Irvine, California) as described by Shao et al. (41) and using previously described calculation methods (42) . Graphic representations and superimpositions were performed by Discovery Studio Modeling Environment, Release 3.5 (Accelrys, Inc., San Diego, California; 2005-2012).
Determination of logD
The apparent pH-dependent distribution partition coefficients (logD) for dissociate mixtures of hexarelin, JMV 1843, JMV 2959, JMV 2810, and L163 255 were calculated by the online Advanced Chemistry Development, Inc. software I-Lab 2.0/LogD module (version 5.0.0.184, 2010 -2013), as previously reported (43) . The structures were drawn with the ACD/ ChemSketch 12 freeware tool and submitted for online calculations to the ACD/I-Lab 2.0/LogD module at the website ilab.acdlabs.com. The logarithm of the apparent octanol-water partition coefficient D for all (including ionized) compound species at various pH values was calculated.
Chemicals
All chemicals cited above as well as ionomycin, caffeine, cyclosporine A (CsA), thapsigargin, and U73122 were purchased from Sigma (St Louis, Missouri). Hexarelin, L163 255 (provided by Merck Research Laboratories, Rahway, New Jersey), JMV1843, JMV2810, and JMV2959 (a kind gift from Dr. Daniel Perrissoud, Aetherna-Zentaris, Frankfurt, Germany), as well as ghrelin (Tocris Cookson Ltd, Bristol, United Kingdom) and [D-Lys-3]-GHRP-6 (Bachem AG, Bubendorf, Switzerland), were freshly dissolved in either normal or calcium-free physiological solution immediately prior to experimentation. Ghrelin, hexarelin, and L163 255 dosages for calcium imaging experiments and the tetrazolium assays evaluating cell viability were chosen based on previous studies (27, 37, 44 -46) .
Statistical analysis
The data are presented as the mean Ϯ SEM. One-way ANOVA, followed by Bonferroni's t test, was used to evaluate multiple statistical differences between groups. P Ͻ .05 was considered to be statistically significant.
Results
Effect of GHSs on intracellular calcium homeostasis of native rat skeletal muscle fibers
Peptidyl and nonpeptidyl GHSs differently affect [Ca
2؉
] i levels In accordance with previous studies (33, 34) 
L163 255-induced calcium increase is independent of GHS-R1a
The different effects mediated by peptidyl and nonpeptidyl GHSs on skeletal muscle calcium homeostasis Figure  2A 
Investigation on the source of L163 255-induced calcium increase
We used the Mn 2ϩ quenching technique to assess the possibility that the L163 255-induced resting calcium increase in muscle fibers could be due to an increase in calcium influx. As shown in Figure 3 , no modification of sarcolemmal permeability to divalent cations was observed after L163 255 treatment. The mean quench rate was 3.3 Ϯ 0.2% min Ϫ1 and 2.9 Ϯ 0.3% min induced by L163 255 is likely due to calcium release from intracellular stores. Thus, we attempted to identify the relevant intracellular sources. In Figure 4B , representative traces showing the L163 255-induced effects in the presence of various pharmacological tools are reported. Initially, we investigated the possible involvement of the sarcoplasmic reticulum (SR) using thapsigargin, which inhibits the Ca 2ϩ -ATPase pump responsible for sequestering Ca 2ϩ in the SR and depletes the store by irreversibly preventing its refilling. After treatment with 10 M thapsigargin, a double application of 40 mM caffeine allowed for SR Ca 2ϩ depletion (data not shown). When 200 M L163 255 was successively applied to the same preparation, an increase of [Ca 2ϩ ] i was observed, although this increase was less intense than that observed in the control fibers ( Figure 4, A and B) . These data indicated that L163 255 partially mobilized Ca 2ϩ from the SR, but another intracellular calcium store was primarily involved. To rule out the possibility that this store was the mitochondria, we evaluated the effect of L163 255 in the presence of CsA, an inhibitor of the mitochondrial permeability transition pore (PTP) (34, 48) . It is well known that mitochondria play a role in calcium homeostasis in skeletal muscle primarily by opening of PTP to induce a mitochondrial calcium efflux (49) . In agreement with a previous study (34) 
Definition of the molecular requisite for nonpeptide GHS-induced calcium increase
To better define the different capabilities of the tested GHSs of interfering with the skeletal muscle Ca 2ϩ signaling machinery with regard to their chemical structure, the pseudopeptoid compound JMV1843 was tested. JMV1843 produced only a slight [Ca 2ϩ ] i increase, resulting in a less potent effect with respect to the nonpeptidyl compounds. Treatment with 200 M JMV1843 stimulated a [Ca 2ϩ ] i increase of 19 Ϯ 3.4 nM ( Figure 1C) . Furthermore, JMV 2959, a nonpeptidyl triazole derivative usually used as a potent GHS-R1a antagonist (50), also altered calcium homeostasis in a similar manner to that of the other tested nonpeptidyl GHS. When compared at a concentration of 200 M (Figure 1C ), JMV2959 induced a significant [Ca 2ϩ ] i increase that overlapped with those induced by L163 255 and JMV2810. These results were consistent with the conclusion that the chemical feature necessary for mediating a GHS-induced calcium increase is the nonpeptidyl structure.
Effect of GHSs on cell viability of C2C12 skeletal muscle cells
Ghrelin and synthetic GHSs have been shown to exert different effects on proliferation and survival in human lung, prostate, skeletal muscle, breast carcinoma, and cancer cell lines (37, 44 -46) . It is well established that unregulated elevation in [Ca 2ϩ ] i may lead to cytotoxicity; thus the effects of peptidyl and nonpeptidyl GHSs on cell viability of C2C12 myoblasts were determined.
Ghrelin and the synthetic peptidyl hexarelin showed no effect on cell viability at any of the doses tested ( Figure 5A ). However, treatment with L163 255 significantly decreased the viability of C2C12 myocytes in a dose-dependent manner ( Figure 5B ). In the presence of 1, 10, 50, and 100 M L163 255, cell viability was significantly decreased by 13 Ϯ 2, 23 Ϯ 3, 52 Ϯ 3, and 96 Ϯ 1%, respectively.
Molecular modeling
To support the experimental observations and to identify the molecular determinants of GHSs likely to affect calcium homeostasis in native skeletal muscle, molecular modeling studies were carried out. Conformational search studies showed that all examined GHSs exhibit a restricted number of low-energy conformers. The lowest energy conformers of each compound are shown in Figure 6A . The molecular overlay between hexarelin and JMV1843 highlights the presence of the amide bond in JMV1843 that confers the nature of pseudopeptoid to this compound usually defined as a modified tripeptide derived by truncating hexarelin (13) . The low-energy conformers of both molecules were characterized by the presence of intramolecular hydrogen bonds between the oxygen atom of the terminal formyl carbonyl group and the hydrogen atom on the amino group of the aminoacylamido group of the pseudopeptide amide bond for JMV1843 and between the terminal amino group of the histidine and the carboxamido oxygen atom of the alanine for hexarelin ( Figure 6B ). Concerning the nonpeptidyl structures, all lower-energy conformer families exhibit the aromatic rings laying on different planes due to their molecular flexibility (Figure 6A) . Particularly, an overlay of the lowest-energy conformers of L163 255, JMV2810, and JMV2959 indicated that all compounds displayed one overlapped spatially oriented aminoacyl group and 2 aromatic areas ( Figure  6C ). With respect to these nonpeptidyl GHSs, JMV1843 shared the aminoacyl group orientation but showed a differential spatial arrangement of the 2 aromatic areas. This latter conformational feature of JMV1843 could be due to the intramolecular hydrogen bonding, which is lacking in nonpeptidyl GHSs, that forces the indole aromatic rings into a more constrained configuration with respect to nonpeptidyl GHSs ( Figure 6D ).
Lipophilicity
The peptide/nonpeptide structure of the GHSs influences their intrinsic physiochemical properties. The partition coefficient (logD) between octanol and aqueous solution at pH 7.4 of each of these compounds was determined as a measure of lipophilicity. Figure 7 shows the relationship of the logD value to drug-induced changes in calcium levels. Nonpeptidyl GHSs demonstrated a comparable capability of inducing [Ca 2ϩ ] i increase in skeletal muscle fibers and showed higher lipophilicity with respect to the peptide hexarelin, each with a logD value ranging from 2-4.
Discussion
Numerous clinical trials involving both ghrelin agonists and antagonists in many type of diseases are currently underway. The primary area of interest involves the stimulation of appetite and fat accumulation by ghrelin and GHSs in wasting diseases and cachexia. However, a number of biological systems may be affected by these treatments as suggested by both the wide distribution of the cloned ghrelin receptor and a number of tissues and cell types known to respond to this hormone through a yet unidentified mechanism. Thus, the understanding of the diverse effects of GHSs on various tissues is pivotal to , n ϭ 16), in the presence of thapsigargin (TPA, n ϭ 18), and in the presence of CsA (n ϭ 15) was reported. Each bar represents the mean Ϯ SEM. Statistical analysis by ANOVA showed significant differences (F ϭ 5; df ϭ 3/95; P Ͻ .005). Symbols represent statistically significant differences by the Bonferroni t test with respect to control (*) and Ø Ca 2ϩ ( # ) (P Ͻ .05 or less). B, Superimposed traces showing the effect of the treatment with 200 M L163 255 in the control condition, in the presence of the Ca 2ϩ -ATPase inhibitor thapsigargin (TPA) (black trace), or in the presence of the mitochondrial PTP inhibitor CsA (gray trace). In the case of TPA, muscle fibers were incubated with 10 M TPA for 15 minutes prior to repeated treatment with 40 mM caffeine, after which L163 255 was added. In the case of CsA, muscle fibers were incubated with 2 M CsA for 10 minutes prior to the addition of L163 255.
develop specific and safe agonists and antagonists targeting the ghrelin system.
Nonpeptidyl GHSs alter calcium homeostasis in skeletal muscle fibers
We demonstrated that GHSs affect skeletal muscle calcium homeostasis depending on their peptidyl or nonpeptidyl structure. Specifically, we showed for the first time that the synthetic nonpeptidyl GHSs under study were able to significantly increase [Ca 2ϩ ] i of native skeletal muscle fibers, whereas peptidyl GHSs did not affect calcium homeostasis. The pseudopeptoid JMV1843 produced only a slight increase of [Ca 2ϩ ] i , further corroborating the hypothesis that the molecular requisite for mediating GHS-induced calcium alteration on skeletal muscle is the nonpeptidyl structure.
Given the pivotal role of calcium ions for muscle functionality, we identified the source of calcium involved in the non-peptidyl GHS-induced effects. The fact that the [Ca 2ϩ ] i rise produced in response to L163 255 occurred in the absence of external Ca 2ϩ demonstrated that the observed cytosolic calcium increase in skeletal muscle fibers resulted from intracellular calcium stores. The lack of effect of L163 255 in Mn 2ϩ quenching experiments also corroborated the involvement of Ca 2ϩ efflux from internal store in the drug mechanism of action. The reduced effect of L163 255 observed in the presence of either thapsigargin/caffeine or CsA led to the notion that the [Ca 2ϩ ] i increase was due to partial calcium release from the SR and primary release from the mitochondria.
It is widely known that excess Ca 2ϩ levels within cells are highly toxic, causing massive activation of proteases and several phospholipases. In various tissues, the PTP opening has been proposed as a likely candidate for Ca 2ϩ -dependent effector of apoptosis (51) . Accordingly, cell viability experiments on C2C12 cells suggested that nonpeptidyl GHSs triggered cell death.
GHSs mechanism of action implications
In contrast to nonpeptidyl GHSs, ghrelin as well as the synthetic peptidyl GHS hexarelin did not alter calcium homeostasis or the viability of skeletal muscle fibers. These findings suggested that the effects of nonpeptidyl GHSs under study were likely not mediated by the cloned ghrelin receptor. Signaling from endogenous and synthetic GHSs is generally considered to occur through the GHSR1a, and this receptor has been found in most tissues and organs of the body, including skeletal muscle (52, 53) . By using [D-Lys-3]-GHRP-6 and U73122, we demonstrated that nonpeptidyl GHSs induced an increase in [Ca 2ϩ ] i through a mechanism that is independent from GHS-R1a activation. However, alternative binding sites for GHSs have been proposed in many types of tissues with different affinities toward the various GHS structures. It has been demonstrated that different GHS-R subtypes or receptor families are expressed in the cardiovascular tissues (54) , and there are both similarities and differences between ghrelin and GHSs in terms of cardiac actions (20) . All of the substances are able to increase cardiac performance either in animals or humans. However, in contrast to the nonpeptidyl GHSs, synthetic peptidyl GHSs and ghrelin itself are able to protect the heart from ischemia. This action appears to be mediated by a receptor specific to the synthetic peptidyl GHSs only (20) . Also in our case, the differential GHS activity could be speculatively attributed to the different affinity of the GHSs to muscle-binding sites. However, based on the finding that JMV2959, a nonpeptide triazole derivative antagonist of GHS-R1a, could induce a calcium increase as well as the postulated high capability of nonpeptidyl GHS crossing the plasma membrane due to their high molecular lipophilicity, we hypothesize that the observed effects on calcium homeostasis are due to a direct activation of an intracellular cascade by these nonpeptidyl GHSs.
Modeling study
We attempted to explain the different effects of the GHSs on skeletal muscle calcium homeostasis by performing modeling investigations that allow us to compare the spatial geometry profiles associated with the tested peptide, pseudopeptoid, and nonpeptidyl GHSs. The most important conclusion is that all nonpeptidyl structures used have common spatial features. Indeed, overlaying the lowest-energy conformers of the nonpeptidyl structures, including the antagonist JMV2959, revealed that all of these compounds display 1 aminoacyl group and 2 hydrophobic aromatic areas similarly oriented.
Regarding nonpeptidyl GHSs, some interesting observations about the structure-calcium homeostasis alteration relationship may be drawn for peptidyl and pseudopeptoid structures. When the GHS type is correlated with the effect observed on skeletal muscle calcium homeostasis, it appears that JMV1843 represents a molecular switch with spatial conformational features between peptidyl and nonpeptidyl structures. Accordingly with the pseudopeptoid structure, the JMV1843 molecule contains an amide bond and an intramolecular hydrogen bond that overlay well with hexarelin. However, in comparison with the nonpeptidyl GHSs, the presence of an overlapped spatially oriented aminoacyl group and of the 2 aromatic areas in JMV1843 could contribute to the slight interference with calcium homeostasis. The different spatial orientations of the 2 aromatic areas with respect to L163 255 and JMV2810, most likely due to a more constrained configuration associated with JMV1843, could account for the reduced ability to induce increases in intracellular calcium levels with respect to nonpeptidyl GHS.
Therapeutic implications and conclusions
Several studies have investigated the involvement of ghrelin and its analogues in wasting conditions, with promising results for therapeutic approaches (4, 6, 7) . Wasting is defined as unintentional weight loss in which both fat-free mass and fat mass are lost, and it is characterized by severe malnutrition, weight loss, muscle atrophy, and anemia (55) . Wasting is often the result of endocrine disorders accompanying the disease process itself. Among the hormonal mediators involved, ghrelin is a peptide that activates neurons of the arcuate nucleus of the hypothalamus, an area known to be important in the regulation of feeding. Regarding skeletal muscle, the continuous demand of efficacious treatment for several muscular degenerative pathologies, makes GHSs promising compounds with high therapeutic interest. Nonetheless, taking into account the wide spectrum of biological actions of GHS molecules, the assessment of the risk-benefit profile for this class of drugs is pivotal from both a therapeutic and toxicological point of view. Here, we demonstrated that the nonpeptidyl molecules L163 255 and JMV2810, but not the peptidyl molecules ghrelin and hexarelin, could affect calcium homeostasis and thus potentially exert detrimental effects on skeletal muscle functionality. The changes in calcium homeostasis induced by these nonpeptidyl GHSs may have multiple consequences that could exacerbate muscle damage. For example, it is widely known that calcium can stimulate muscle protein breakdown by increasing calpain and proteasome activity (56 -58) as well as activate various transcription factors and nuclear cofactors that regulate gene transcription (59) . From a pathophysiological point of view, changes in calcium homeostasis may be responsible for functional muscle loss. Accordingly, during aging, either in fast-or slowtwitch muscle fibers, the abnormally increased resting calcium concentration (60) induces the activation of Ca 2ϩ -dependent proteases, which may contribute to sarcopenia and the clinically reported reduced muscle strength and exercise capacity typical of this condition. Thus, the nonpeptidyl GHSs under study could potentially exert direct effects on muscle functionality, which could counterbalance the beneficial effects associated with these drugs in the treatment of muscle wasting syndromes. Indeed, in cachexia and sarcopenia, the involvement of apoptosis though either DNA fragmentation or a significant calcium-dependent up-regulation of caspase activity appears to be widely proven (61, 62) . It should be underlined that our data referred to the effect of some GHSs acutely applied in vitro. However, in vivo studies are needed to assess the detrimental effects on muscle functionality due to GHSs interference with calcium homeostasis. Further studies are also necessary to clarify whether the calciuminduced changes are a common feature of all nonpeptidyl GHSs. However, the effect of L163 255 on [Ca 2ϩ ] i and cell proliferation may provide a plausible link with the data reported by Bach et al. (63) . MK-0677 treatment in older individuals who sustained a hip fracture did not produce clinically significant effects on physical function, although an increased in serum IGF-1 level was observed. In view of the molecular structure, it would be feasible that MK-0677, with a mechanism similar to that of the nonpeptidyl compounds used in this study, could affect calcium homeostasis and muscle function.
Furthermore, the lack of effects of the peptidyl GHSs on calcium homeostasis led us to define this class of GHSs as potentially safer than nonpeptidyl compounds. Also in this case, in vivo studies are needed to assess this hypothesis and to elucidate the clinical benefit associated with these molecules. Nevertheless, some previous in vivo studies do support our hypothesis. Indeed, according to the present results, the increase in expression of the 2 musclespecific ubiquitin ligases, muscle RING-finger protein-1 (MuRF1) and atrogin-1/muscle atrophy F-box (MAFbx), seen in some models of cachexia and muscular wasting, was either normalized or prevented after the administration of ghrelin or peptidyl GHSs (38, 64, 65) . Furthermore, it has been recently reported that in vivo ghrelin administration to animals and humans produced significant anticachectic effects (66 -68) . Any beneficial effect at these levels was reported with nonpeptidyl GHSs.
In summary, our study demonstrated that GHSs can differently affect skeletal muscle fibers depending on their molecular structure. The dysregulation in calcium homeostasis specifically induced by nonpeptidyl GHSs used in this study could potentially counterbalance the beneficial effects associated with these drugs in the treatment of muscle wasting in cachexia-or other age-related disorders.
